- CCT137690
- MK-8745
- MLN8237 (Alisertib)
- Aurora A Inhibitor I
- MK-5108 (VX-689)
- MLN8054
| AT9283Aurora kinase/JAK inhibitor |

Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.
Nature.2018 Jun 13.
Nature.2018 Jun 27.
Nature.2018 Mar 29;555(7698):673-677.
Nature.2017 Sep 7;549(7670):96-100.
Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8
Nat Nanotechnol.2017 Dec;12(12):1190-1198.
Nature Biotechnology.2017 Jun;35(6):569-576
Nat Med.2018 Sep 17.
Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.
Cell.Available online 25 October 2018.
Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.
Cell.2018 Jun 28;174(1):172-186.e21.
Cell.2018 Feb 22;172(5):1007-1021.e17.
Cell.2017 Nov 30;171(6):1284-1300.e21.
Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.
Cell.2017 Jul 13;170(2):312-323
Nat Med.2018 Jan 29.
Nat Med.2017 Nov;23(11):1342-1351.
Cell.2017 Apr 6;169(2):286-300.
Cell.2015 Aug 27;162(5):987-1002.
Cell.2015 Feb 12;160(4):729-44.
Nature Medicine.2017 Apr;23(4):493-500.
Cancer Cell.2018 May 14;33(5):905-921.e5.
Cancer Cell.2018 Apr 9;33(4):752-769.e8.
Cancer Cell.2018 Mar 12;33(3):401-416.e8.
Cancer Cell.2017 Aug 14;32(2):253-267.e5.
Nat Methods.2018 Jul;15(7):523-526.
Cell Stem Cell.2018 May 3;22(5):769-778.e4.
Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure

| Description | AT9283 is a potent inhibitor of Aurora with IC50 values of 3 nM, 3 nM, 1.1 nM, 1.2 nM and 4 nM for Aurora A, Aurora B, JAK3, JAK2 and c-Abl, respectively. | |||||
| Targets | Aurora A | Aurora B | JAK3 | JAK2 | c-Abl | |
| IC50 | 3 nM | 3 nM | 1.1 nM | 1.2 nM | 4 nM | |

AT9283 Dilution Calculator
calculate

AT9283 Molarity Calculator
calculate
| Cas No. | 896466-04-9 | SDF | Download SDF |
| Chemical Name | 1-cyclopropyl-3-[(3Z)-3-[5-(morpholin-4-ylmethyl)benzimidazol-2-ylidene]-1,2-dihydropyrazol-4-yl]urea | ||
| Canonical SMILES | C1CC1NC(=O)NC2=CNNC2=C3N=C4C=CC(=CC4=N3)CN5CCOCC5 | ||
| Formula | C19H23N7O2 | M.Wt | 381.43 |
| Solubility | ≥19.05 mg/mL in DMSO, ≥47.6 mg/mL in EtOH with ultrasonic, <2.3 mg/ml="" in="" h2o="">2.3> | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
AT9283, a synthetic small heterocyclic molecule discovered using a fragment-based approach, is a novel inhibitor of aurora kinase, a family of serine/threonine kinases regulating both mitosis and meiosis, that potently inhibits Aurora kinases A and B, with 50% inhibition concentration IC50 value of 3 nM, as well as Janus kinases (JAKs), Abelson kinase (BCRABL T315I) and Flt-3. AT9283 has been found to be therapeutic in leukemic cells, myeloproliferative disorders and multiple solid tumor cell lines. Study results have shown that AT9283 exhibits anti-proliferative activity and induces polyploidy and apoptosis in aggressive B-cell NHL cell lines associated with inhibition of Aurora kinase B.
Reference
Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. Epub 2011 Nov 19.
Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol. 2012 May;23(5):1307-13. doi: 10.1093/annonc/mdr451. Epub 2011 Oct 19.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
我的邮箱:maoyuanqing@citiz.net
**捷向您推荐美国Trevigen的一款通用PARP分析试剂盒检测试剂盒。该试剂盒是检测凋亡前与凋亡中细胞提取液中PARP活性的理想方案,操作简单,重复性高。其通过检测96孔板上生物素标记的多聚ADP核糖聚合到邻近组蛋白的反应,从而确定已知的或可能的PARP抑制剂。试剂盒中的依托泊苷(Etoposide)是拓扑异构酶Ⅱ抑制剂,在拓扑异构酶Ⅱ切割完DNA后能够稳定该酶。在试剂盒中,依托泊苷作为凋亡诱导的对照参与检测。
通量PARP/凋亡分析试剂盒可广泛应用于1)检测原代、肿瘤等细胞的PARP活性;2)检测凋亡前后的PARP活性;3)利用细胞裂解液筛选PARP抑制剂。
试剂盒特色比色法/化学发光法,无放射性输出。96well,高通量检测。极大地节省了分析时间,提高了使用效率。高敏感性。能够检测到500个细胞中低至0.1mU的PARP。检测范围广。0.1-10mU。样本用量少。仅仅需要10-100ng的提取物。检测时间短。仅需要3h即可完成检测。
**捷向您提供一站式的PARP相关实验解决方案,除了高通量PARP/凋亡分析试剂盒,还有PARP体内药理动力学二代分析试剂盒(PDAII)和通用PAPR分析试剂盒外(含组蛋白包被可拆卸板),以及相关抗体和重组蛋白。
Trevigen是一家快速成长的美国生物技术公司,专注于细胞凋亡、DNA损伤和修复、肿瘤细胞功能与行为等方面研究的肿瘤研究产品和服务。作为Trevigen在中国区域的总代理,**捷与Trevigen一道为中国的科研工作者提供最好、最新的氧化应激、细胞损伤和肿瘤细胞行为研究等领域内的优质产品和技术服务。如果您对上述产品及方案感兴趣,请致电400-6800-868至**捷科技有限公司垂询血管生成研究的相关实验解决方案,或索取最新的产品资料。
A.优点:
多重分析——一次分析可以检测16种干细胞相关的TF
定量比较——二个样本的差异可以定量分析和比较
步骤简单——探针温育、柱分离、板杂交和HRP检测
无需贵重仪器——无需如Luminex那样的贵重仪器
B.原理:
干细胞转录因子活性多重检测阵列试剂用于同时检测多种TF活性。该技术中,基于TFDNA结合位点的一致性序列,制备一系列生物素标记的探针。当探针混合物与核提取物一起温育时,每个探针寻找相应的TF,形成TF/探针复合物,通过柱离心纯化可以很容易与游离探针分开。结合的探针从混合物中分离出来,通过板杂交分析。板孔中预包被上与探针互补的特异序列,捕获的DNA探针进一步用链酶亲和素-HRP检测,化学发光检测仪测定发光强度(RLUs)。

